LOGO.jpg
QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
April 12, 2022 08:00 ET | QSAM Biosciences Inc.
Austin, TX, April 12, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Qualigen-Logo-Tag.png
QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING
November 29, 2021 15:50 ET | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer,...
Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position
March 09, 2021 08:30 ET | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Cytovia.png
Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March
March 08, 2021 10:24 ET | Cytovia Therapeutics
CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric...
Cytovia.png
Cytovia Therapeutics to Present at Jefferies Virtual London Healthcare Conference
November 12, 2020 07:30 ET | Cytovia Therapeutics
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in the...
Cytovia.png
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer
June 03, 2020 13:25 ET | Cytovia Therapeutics
NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces...
Cytovia.png
CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics
January 09, 2020 08:00 ET | Cytovia Therapeutics
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The New York Stem Cell Foundation (NYSCF) Research Institute today announced a partnership with Cytovia Therapeutics Inc. (Cytovia) to develop new disease...